[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Enzalutamide Reviewed in New Cutting-Edge Genericsweb Pipeline Selector Report Now Available at MarketPublishers.com

06 Dec 2012 • by Natalie Aster

LONDON – Enzalutamide (under the code name MDV-3100) is a medication designed for the treatment of castration-resistant prostate cancer in men for whom docetaxel-based chemotherapy has failed. Belonging to a class of androgen receptor inhibitors, the drug works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of cancer cells.

Medivation Inc and Japan-based Astellas will be engaged in the development and marketing of the drug in the US under a 2009 marketing agreement.

New report “MDV-3100 (Enzalutamide) - Key patent, SPC, and data exclusivity expiry (44 country coverage)” elaborated by Genericsweb covers MDV-3100 (Enzalutamide), including key patents, extensions and data exclusivity expiry for 44 countries, regulatory issues and key players.

Report Scope:

  • coverage of key patent publications for 44 countries; 
  • information on SPC protection for every EU state plus patent term extensions in other countries; 
  • data exclusivity calculated on a country by country basis; 
  • summary of dosage forms, strengths, indications and active ingredient forms of the brand product; 
  • DMF & Paragraph IV filings; 
  • litigation alerts; 
  • marketing authorisation holders in the UK, the US, Canada and Australia; 
  • patent risk analysis via three graphical displays of data from known patent filings; 
  • hyper-linking to crucial patent documents and national registries enabling data verification.

Report Details:

MDV-3100 (Enzalutamide) - Key patent, SPC, and data exclusivity expiry (44 country coverage)
Published: December, 2012
Price: US$ 1.200,00

More Pipeline Selector Reports by Genericsweb are Also Available:

More new pipeline reports by the publisher can be found at Genericsweb page.


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest